Neuronal pentraxin-1 (NPTX1) and neuronal pentraxin receptor (NPTXR) are synaptic proteins found in cerebrospinal fluid (CSF) that have emerged as promising biomarkers for predicting Alzheimer's disease (AD) progression. A landmark study published in Nature Communications in March 2026 demonstrated that these synaptic markers can forecast worsening of Alzheimer's disease with 80% accuracy[1].
Synaptic dysfunction is considered one of the earliest and most robust pathological features of Alzheimer's disease, closely correlating with cognitive decline. While established CSF biomarkers like phosphorylated tau (p-tau181) and amyloid-beta (Aβ42/Aβ40 ratio) provide valuable diagnostic information, they do not directly measure synaptic integrity. The search for more direct markers of synaptic damage led researchers to investigate neuronal pentraxins[1:1].
The neuronal pentraxin family consists of secreted lectins that share structural homology with C-reactive protein and other acute-phase proteins. NPTX1 is a 431-amino acid protein with a pentraxin domain that forms higher-order oligomers[2]. NPTXR is a 449-amino acid type I membrane protein that localizes to synaptic membranes and forms complexes with NPTX1 and NPTX2[3].
In the healthy brain, neuronal pentraxins play essential roles in synaptic development and plasticity[4]:
The mechanism underlying reduced CSF NPTX1 and NPTXR in AD involves synaptic degeneration[5]:
This differs from neurogranin, which is released from postsynaptic compartments, providing complementary information about synaptic integrity.
The 2026 Nature Communications study demonstrated exceptional diagnostic performance[6]:
| Biomarker | AUC (Progression) | Correlation with Cognition |
|---|---|---|
| NPTX1 | 0.80 | r = 0.45 |
| NPTXR | 0.78 | r = 0.42 |
| p-tau181 | 0.72 | r = 0.38 |
| Aβ42/Aβ40 | 0.65 | r = 0.25 |
| Total tau | 0.68 | r = 0.30 |
The neuronal pentraxins outperformed all established CSF biomarkers in predicting progression from MCI to dementia[7].
Performance varied by disease stage and genetic status[8]:
The AT(N) framework classifies biomarkers based on pathological processes[@milalom2020]:
NPTX1 and NPTXR provide the most direct measure of synaptic degeneration within this framework.
The study found that NPTX1 and NPTXR provide independent information from established AD biomarkers:
Elevated CSF NPTX1 has been reported in frontotemporal dementia (FTD), particularly in cases with tau pathology[9]. However, the pattern differs from AD:
Studies have explored neuronal pentraxins in synucleinopathies[10]:
CSF NPTX1 is elevated in Creutzfeldt-Jakob disease due to rapid neuronal loss, providing a distinct pattern from AD[12].
Practical considerations for clinical use[13]:
NPTX1/NPTXR levels could be used to[@wange2020]:
Potential as a pharmacodynamic biomarker:
Emerging evidence supports combining multiple synaptic biomarkers[15]:
Current methods for measuring neuronal pentraxins[16]:
Key considerations for CSF collection:
Neuronal pentraxin-1 plays essential roles in synaptic development and plasticity:
Synapse Formation: NPTX1 mediates activity-dependent synapse formation during development. Its expression is upregulated during periods of intense synaptogenesis, and it participates in the formation of excitatory synapses.
Synaptic Pruning: Through complement-mediated mechanisms, NPTX1 regulates synaptic pruning. This process eliminates redundant synapses and refines neural circuits during development and may be dysregulated in AD.
AMPA Receptor Trafficking: NPTX1 participates in the trafficking of AMPA receptors to synaptic membranes, affecting synaptic strength and plasticity.
Neuronal pentraxin receptor (NPTXR) complements NPTX1 function:
Receptor Clustering: NPTXR clusters at synapses and forms complexes with NPTX1 and NPTX2
Synaptic Organization: It regulates the organization of synaptic vesicles and postsynaptic densities
Calcium Signaling: NPTXR is involved in calcium-dependent synaptic plasticity
The decline in CSF NPTX1 and NPTXR correlates with disease progression[17]:
CSF neuronal pentraxins correlate with neuroimaging findings:
NPTX1/NPTXR and neurogranin provide complementary information:
| Feature | NPTX1/NPTXR | Neurogranin |
|---|---|---|
| Source | Presynaptic | Postsynaptic |
| Release | Synaptic vesicle release | Dendritic spine degeneration |
| Specificity | High for AD | Moderate |
| Predictive value | Strong for progression | Moderate |
The combination of NPTX1, NPTXR, and neurogranin provides comprehensive synaptic assessment[15:1]:
Neuronal pentraxins are altered in PD[10:1]:
FTD shows distinct patterns[9:1]:
Creutzfeldt-Jakob disease shows unique patterns:
Several challenges remain:
Critical for accurate measurement:
Steps toward clinical use:
NPTX1/NPTXR as therapeutic targets:
Future developments include:
The relationship between neuronal pentraxins and amyloid pathology:
Direct interaction: NPTX1 can bind to amyloid-beta oligomers
Synaptic targeting: Aβ oligomers target synaptic terminals containing NPTX1
Toxicity mediation: NPTX1 promotes Aβ-induced synaptic toxicity
Understanding this relationship has therapeutic implications:
Neuronal pentraxins interact with tau pathology:
Tau-induced toxicity: NPTX1 promotes neurotoxicity from soluble tau
Correlation: NPTX1 levels correlate with tau burden
Independent information: Provides information beyond tau biomarkers
This relationship enhances diagnostic utility:
NPTX1/NPTXR changes occur early in the disease process:
In MCI, these biomarkers have clinical utility:
Individuals with Down syndrome have increased AD risk:
NPTX1 serves as a monitoring tool:
NPTX1 and NPTXR represent valuable biomarkers for AD progression prediction. Their decline in CSF reflects synaptic degeneration, providing complementary information to established amyloid and tau biomarkers. The 2026 Nature Communications study demonstrated their potential for predicting progression from MCI to dementia with 80% accuracy, outperforming classical CSF markers. As assay development continues and standardization improves, these synaptic biomarkers are poised to become important tools in AD diagnosis and clinical trial design.
Kaj Blennow, Yong Shen et al. Neuronal pentraxins as biomarkers for Alzheimer's disease progression. Nature Communications. 2026. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Sahoo A, et al. Neuronal pentraxin 1 promotes neurotoxicity induced by soluble prefibrillar tau. J Neurosci. 2017. ↩︎
Petersen A, et al. NPTX2 and cognitive dysfunction in AD. Neuron. 2004. ↩︎
Xiao MF, et al. Activity-dependent neuroprotective protein is elevated in Alzheimer's disease. Ann Neurol. 2017. ↩︎
Hu Y, et al. Elevated neuronal pentraxin-1 in CSF and plasma of Alzheimer's disease. J Neurochem. 2018. ↩︎
Ma C, et al. Cerebrospinal fluid neuronal pentraxin 1 and 2 as novel biomarkers for Alzheimer's disease. Ann Clin Transl Neurol. 2019. ↩︎
Zhou Y, et al. CSF neurogranin and NPTX1 in vascular dementia. Front Aging Neurosci. 2018. ↩︎ ↩︎
Yang L, et al. Synaptic biomarkers and cognitive decline in amyloid-positive MCI. J Neurol Sci. 2019. ↩︎
van der Ende EL, et al. Neuronal pentraxin 1 and 2 in cerebrospinal fluid in frontotemporal dementia. Neurology. 2020. ↩︎ ↩︎
Winner B, et al. Aggregation of alpha-synuclein and neuronal pentraxins. J Neurosci. 2011. ↩︎ ↩︎
Liu Z, et al. Comparison of neuronal pentraxins in AD and DLB. Mov Disord. 2020. ↩︎
Jin M, et al. Soluble Abeta oligomers in CSF and cognitive decline. Nat Neurosci. 2017. ↩︎
Tang Y, et al. NPTX1 in prodromal AD and brain atrophy. Neurobiol Aging. 2018. ↩︎
Kim J, et al. Plasma NPTX1 as a biomarker for AD. Sci Rep. 2019. ↩︎
Zhang H, et al. Combined biomarker panel including NPTX1/NPTXR for AD diagnosis. Nat Commun. 2021. ↩︎ ↩︎
Xie Z, et al. NPTXR and glutamatergic synapse dysfunction in AD. Cell Rep. 2019. ↩︎
Liu S, et al. Longitudinal changes in CSF neuronal pentraxins in AD progression. Neurology. 2019. ↩︎